Please assess the completion status of the following clinical trial:

Trial Title: Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have diagnosis of EoE (based on consensus criteria)~* Are aged 6 to 17 years~* Have histologically confirmed active disease \>15 eosinophils/hpf in either distal or proximal esophagus within 12 weeks of screening visit~* Proton Pump Inhibitor (PPI) confirmation~* Symptomatic (have experienced symptoms within the last month prior to enrollment)~* Has a negative urine pregnancy test at screening if of childbearing potential. Females of childbearing potential must have a negative urine pregnancy test (β-hCG) prior to enrollment into the study (i.e., at screening). Subsequently, these participants must agree to use adequate birth control measures (e.g., condom, oral/injectable/subcutaneous contraceptives, intrauterine device, or sexual abstinence) during the study and for at least one month after the last dose of study drug which will be documented in the source documents.~Exclusion Criteria:~* Have been treated with topical swallowed steroids within the last 2 months or systemic steroids within the past 3 months~* Have eosinophilia in segments of the GI tract other than the esophagus~* Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory bowel disease, Crohn's disease) or Celiac disease~* Are currently on dietary therapy avoiding milk~* Have concurrent H pylori gastritis or parasitic infection~* Are unable to obtain esophagogastroduodenoscopy with esophageal biopsies at Cincinnati Children's Hospital Medical Center (CCHMC) or other participating institution within 4 weeks of study completion~* Have previously failed (in a clinical trial setting) dietary therapy with one of these regimens or topical steroid treatment with fluticasone at a total dose of 1760 mcg per day.~* Have definitely responded (in a clinical trial setting) to either dietary therapy avoiding these antigens or to swallowed fluticasone at a total dose of 1760 mcg per day~* Are concurrently receiving any of the prohibited medications listed in Table 2~* On immunotherapy for pollen (if not on maintenance therapy) or immunoglobulin E (IgE)-mediated food allergy.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1FED (Type: ACTIVE_COMPARATOR): 1-food elimination diet: Participants eliminate milk from the diet in Phase 1
- 4FED (Type: ACTIVE_COMPARATOR): 4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
- 1FED Non-Responders (4FED) (Type: OTHER): Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
- 4FED Non-Responders (SGC) (Type: OTHER): Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2

Based on this trial design, predict the completion outcome and termination type (if applicable).